• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA OKs expanded trial for Precision Biopsy’s ClariCore prostate biopsy device

FDA OKs expanded trial for Precision Biopsy’s ClariCore prostate biopsy device

September 12, 2016 By Fink Densford

Precision BiopsyPrecision Biopsy said today it won an investigational device exemption from the FDA to expand the trial of its ClariCore biopsy system, now looking to enroll prostate cancer patients in the newly cleared Transrectal Ultrasound and MR/Fusion arms of the study.

The ClariCore system is designed for the spectral analysis of tissue samples during biopsies to “rapidly classify” tissue as normal or suspicious using an optical fiber and companion console designed to minimize the number of samples taken by up to 90%, the company said.

“The approval from the FDA marks an important step forward in our efforts to finalize development of the ClariCore Optical Biopsy System and help to improve the biopsy process for patients being evaluated and monitored for prostate cancer, the second-most deadly cancer in men,” CEO Amir Tehrani said in a press release.

The Aurora, Colo.-based company said it has already enrolled 33 patients in its retropubic radical prostatectomy arm of the study.

The company’s approximately 200-patient trial of the ClariCore system aims to collect prostate tissue and associated optical signatures to help develop the systems’ real-time tissue classification algorithm.

“We are looking forward to enrolling prostate biopsy patients in the Cohort A clinical trial using the ClariCore Optical Biopsy system. ClariCore is a breakthrough technology that should both benefit patient outcomes and also reduce healthcare costs,” Dr. Neal Shore of the Carolina Urologic Research Center said in prepared remarks.

“The ability to expand the trial is an important milestone in the development of the ClariCore system and we are excited by the progress achieved by the Precision Biopsy team,” Precision Biopsy parent company Allied Minds senior veep Dr. Omar Amirana said in a prepared statement.

Precision Biopsy applied for the expansion in March, looking to add the Transrectal Ultrasound and MR/Fusion arms to collect data from prostate cancer patients.

All 3 arms of the company’s Cohort A clinical trial look to collect prostate tissue and associated optical responses to help develop the ClariCore System’s real-time tissue classification algorithm, the company said. A total of 200 patients are slated to be enrolled in the algorithm development trial.

Last October, Precision Biopsy said it raised $33.6 million in a new round of equity financing to support its ClariCore biopsy platform designed to provide prostate tissue classification during biopsy procedures.

Woodford Investment Management led the round, according to Aurora, Colo.-based Precision Biopsy, with investments from its parent company Allied Minds.

Filed Under: Clinical Trials, Food & Drug Administration (FDA), Regulatory/Compliance, Software / IT Tagged With: Precision Biopsy

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy